{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:43:54Z","timestamp":1789537434888,"version":"build-2803163510"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T00:00:00Z","timestamp":1496880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ijidonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ijid.2017.06.007","type":"journal-article","created":{"date-parts":[[2017,6,11]],"date-time":"2017-06-11T00:45:16Z","timestamp":1497141916000},"page":"39-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"special_numbering":"C","title":["Comparison of antimicrobial activity between ceftolozane\u2013tazobactam and ceftazidime\u2013avibactam against multidrug-resistant isolates of Escherichia coli , Klebsiella pneumoniae , and Pseudomonas aeruginosa"],"prefix":"10.1016","volume":"62","author":[{"given":"Adnan","family":"Alatoom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hashim","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Lawlor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"AbdelWareth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania","family":"El-Lababidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lysettee","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Mooty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Fernanda","family":"Bonilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Nusair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijid.2017.06.007_bib0005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/2047-2994-1-26","article-title":"The prevalence of antimicrobial resistance in clinical isolates from Gulf Corporation Council countries","volume":"1","author":"Aly","year":"2012","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.ijid.2017.06.007_bib0010","series-title":"Zerbaxa\u2122 (ceftolozane sulfate; tazobactam sodium) [package insert]","author":"Anon","year":"2015"},{"key":"10.1016\/j.ijid.2017.06.007_bib0015","series-title":"Avycaz\u2122 (avibactam sodium; ceftazidime) [package insert]","author":"Anon","year":"2015"},{"key":"10.1016\/j.ijid.2017.06.007_bib0020","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/AAC.01802-13","article-title":"Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011\u20132012)","volume":"57","author":"Farrell","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2017.06.007_bib0025","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/jac\/dku025","article-title":"Ceftazidime\/avibactam activity tested against gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012)","volume":"69","author":"Flamm","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2017.06.007_bib0030","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.2147\/TCRM.S120811","article-title":"Ceftolozane\/tazobactam and ceftazidime\/avibactam for the treatment of complicated intra-abdominal infections","volume":"12","author":"Goodlet","year":"2016","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.ijid.2017.06.007_bib0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/CE.S40698","article-title":"Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections","volume":"9","author":"Lagace-Wiens","year":"2014","journal-title":"Core Evid"},{"key":"10.1016\/j.ijid.2017.06.007_bib0040","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ijantimicag.2015.05.003","article-title":"Ceftolozane\/tazobactam and ceftazidime\/avibactam: two novel beta-lactam\/beta-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections","volume":"46","author":"Liscio","year":"2015","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.ijid.2017.06.007_bib0045","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2017.06.007_bib0050","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1128\/AAC.05136-14","article-title":"Activity of Ceftazidime-avibactam against fluoroquinolone-resistant Enterobacteriaceae and Pseudomonas aeruginosa","volume":"59","author":"Pitart","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2017.06.007_bib0055","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/jac\/dku184","article-title":"Antimicrobial activity of ceftolozane\/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12)","volume":"69","author":"Sader","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2017.06.007_bib0060","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1128\/AAC.05024-14","article-title":"Ceftazidime-Avibactam Activity against Multidrug-Resistant Pseudomonas aeruginosa Isolated in U.S. Medical Centersin 2012 and 2013","volume":"59","author":"Sader","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2017.06.007_bib0065","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1099\/jmm.0.059014-0","article-title":"Emergence and spread of NDM-1 producer Enterobacteriaceae with contribution of IncX3 plasmids in the United Arab Emirates","volume":"62","author":"Sonnevend","year":"2013","journal-title":"J Med Microbiol"},{"issue":"2","key":"10.1016\/j.ijid.2017.06.007_bib0070","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1099\/jmm.0.077834-0","article-title":"The molecular basis of \u03b2-lactamase production in Gram-negative bacteria from Saudi Arabia","volume":"64","author":"Yezli","year":"2015","journal-title":"J Med Microbiol"},{"issue":"5","key":"10.1016\/j.ijid.2017.06.007_bib0075","first-page":"226","article-title":"Dissemination of carbapenemases producing Gram negative bacteria in the Middle East","volume":"7","author":"Zahedi-bialvaei","year":"2015","journal-title":"Iran J Microbiol"},{"key":"10.1016\/j.ijid.2017.06.007_bib0080","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1128\/CMR.00096-12","article-title":"\u03b2-Lactamase production in key gram-negative pathogen isolates from the Arabian Peninsula","volume":"26","author":"Zowawi","year":"2013","journal-title":"Clin Microbiol Rev"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971217301613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971217301613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T19:55:06Z","timestamp":1535745306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971217301613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":16,"alternative-id":["S1201971217301613"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2017.06.007","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of antimicrobial activity between ceftolozane\u2013tazobactam and ceftazidime\u2013avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2017.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}